Pharma BD Deal Intelligence
Thermo Fisher's $2.1B all-cash buy of Dionex has held up as a durable bolt-on: the ion chromatography brand is still invested in 13+ years later, with a new Dionex-branded system launched as recently as February 2024 and no impairment or divestiture on record.
Industry coverage characterized the deal as a logical bolt-on giving Thermo a defensible IC franchise and the Chromeleon software stack as a data-management…
Thermo Fisher to pay $118.50/share (~$2.1B) for Dionex, targeting $60M year-three synergies and $0.13-0.15 first-year EPS accretion; Dionex's IC and Chromeleon…
Thermo Fisher closed the Dionex acquisition after extended antitrust review, completing a deal seen as immediately accretive and strategically important for…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Thermo Fisher to acquire Dionex for $118.50/share cash, ~$2.1B. Strengthens chromatography portfolio complementing mass spec/LIMS leadership.
Assessment window: 5yr post-close.
$170M LC-MS water analysis applications market 2010 (USD)
Analytical chromatography instruments separate, identify, and quantify chemical components in samples and are core tools in pharma QA/QC, environmental monitoring, food safety, water analysis, and life sciences research. Ion chromatography (IC) is a specialized technique pioneered by Dionex in 1975 for ionic species in water and biological matrices.
At deal time (Dec 2010) the analytical instruments market was led by Agilent Technologies (post-Varian acquisition, dominant in HPLC and GC), Waters Corporation (LC and LC-MS leader), Thermo Fisher Scientific (mass spec leader, gas chromatography), Shimadzu, and PerkinElmer. Dionex held a near-monopoly in ion chromatography (IC) — a niche but high-margin segment for water-quality testing, pharma counter-ion analysis, and food safety — and ran a respected liquid chromatography business including Chromeleon, the gold-standard chromatography data system. Thermo's $118.50/share, ~$2.1B all-cash offer added IC capability Thermo lacked, paired Chromeleon software with Thermo's mass spec hardware to deliver integrated HPLC-IC-MS workflows, and reinforced Thermo's positioning in water-quality, consumer safety, and life sciences against Agilent and Waters. Thermo guided $60M of year-3 operating synergies and $0.13-0.15 first-year EPS accretion. The deal closed in May 2011 after antitrust review extended the original Q1 2011 timeline. Dionex became the foundation of Thermo's chromatography franchise, complementing later builds in mass spec and the eventual 2017 Patheon acquisition that anchored its CDMO platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / Dionex Corporation (this deal) | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Brammer Bio | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2010 deals · Thermo Fisher Scientific Inc. deals · Other deals